1 unchanged sentence
Issuer Purchases of Equity Securities
−Removed: The table below reflects shares of Common Stock we repurchased under our share repurchase program, as well as Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans, during the three months ended September 30, 2021.
+Added: The table below reflects shares of Common Stock we repurchased under our share repurchase program, as well as Common Stock withheld by us for employees to satisfy their tax withholding obligations arising upon the vesting of restricted stock granted under one of our long-term incentive plans, during the three months ended March 31, 2022.
Refer to Part I, Item 2.
"Management's Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources" for further details of the share repurchase program.
−Removed: Period Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as Part of a Publicly Announced Program Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program
+Added: Period Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as Part of Publicly Announced Programs Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs
+Added: (in millions)
1/1/2022–1/31/2022 240,319 $ 613.11 240,000 $ 2,697.8
2/1/2022–2/28/2022 184,306 $ 618.22 184,200 $ 2,584.0
+Added: 3/1/2022–3/31/2022 142,773 $ 636.92 142,773 $ 2,493.0
Total 567,398 (a)
1 unchanged sentence
Exhibit Number Description
−Removed: 10.1* Modification P00004 to Supply Agreement, dated as of July 26, 2021, by and between Regeneron Pharmaceuticals, Inc.
−Removed: (the "Registrant") and the U.S.
−Removed: Army Contracting Command, New Jersey.
−Removed: 10.2* Modification P00005 to Supply Agreement, dated as of September 14, 2021, by and between the Registrant and the U.S.
+Added: 10.1* Second Amended and Restated Participation Agreement, dated as of March 2, 2022, by and among Old Saw Mill Holdings LLC, as lessee, Bank of America, N.A., as administrative agent, BA Leasing BSC, LLC, as lessor, and the rent assignees party thereto from time to time.
+Added: (Incorporated by reference from the Form 8-K for the Registrant, filed March 8, 2022 .)
+Added: 10.2* Second Amended and Restated Lease and Remedies Agreement, dated as of March 2, 2022, between Old Saw Mill Holdings LLC, as lessee, and BA Leasing BSC, LLC, as lessor.
+Added: (Incorporated by reference from the Form 8-K for the Registrant, filed March 8, 2022.)
+Added: 10.3* Second Amended and Restated Guaranty, dated as of March 2, 2022, made by Regeneron Pharmaceuticals, Inc.
+Added: (the "Registrant"), Regeneron Healthcare Solutions, Inc., and Regeneron Genetics Center LLC, as guarantors.
+Added: (Incorporated by reference from the Form 8-K for the Registrant, filed March 8, 2022.)
+Added: 10.4 Modification No.
+Added: 1 to Base Agreement, dated as of January 26, 2022, by and between the Registrant and Advanced Technology International.
+Added: 10.5** Modification No.
+Added: 5 to Project Agreement, dated as of March 22, 2022, by and between the Registrant and Advanced Technology International.
+Added: 10.6** Modification P00006 to Supply Agreement, dated as of February 24, 2022, by and between the Registrant and the U.S.
Army Contracting Command, New Jersey.
4 unchanged sentences
101 Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language ("Inline XBRL"):
−Removed: (i) the Registrant's Condensed Consolidated Balance Sheets as of September 30, 2021 and December 31, 2020;
−Removed: (ii) the Registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three and nine months ended September 30, 2021 and 2020;
−Removed: (iii) the Registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2021 and 2020;
−Removed: (iv) the Registrant's Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2021 and 2020;
+Added: (i) the Registrant's Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021;
+Added: (ii) the Registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three months ended March 31, 2022 and 2021;
+Added: (iii) the Registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2022 and 2021;
+Added: (iv) the Registrant's Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021;
and (v) the notes to the Registrant's Condensed Consolidated Financial Statements.
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
+Added: * Certain of the exhibits and/or schedules to this exhibit were omitted in accordance with Item 601(a)(5) of Regulation S-K
** Certain confidential portions of this exhibit were omitted in accordance with Item 601(b)(10) of Regulation S-K
1 unchanged sentence
REGENERON PHARMACEUTICALS, INC.
−Removed: November 4, 2021 By:
+Added: May 4, 2022 By:
/s/ Robert E.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.